Shachar Eini Nachmani

When the parents of an 8-year-old boy reached out, researchers at Tel Aviv University responded with science. A team from the Gray Faculty of Medical & Health Sciences | הפקולטה למדעי הרפואה והבריאות ע"ש גריי, led by Prof. Moran Rubinstein and Prof. Karen B. Avraham, developed the first mouse model for an extremely rare and fatal genetic disease affecting just 40 people worldwide. This model now enables deeper understanding of the disease and offers a platform to test new drug and gene therapies, bringing real hope to patients and families: https://lnkd.in/erK4dd3A #rarediseases #geneticdiseases #genetherapy #geneinnovation #medtech #healthtech #healthinnovation #innovation

47

‏1‏ ‏תגובה‏

𝗙𝗶𝗻𝗮𝗻𝗰𝗶𝗮𝗹 𝗯𝗮𝗿𝗿𝗶𝗲𝗿𝘀 𝗮𝗿𝗲 𝗼𝗳𝘁𝗲𝗻 𝘁𝗵𝗲 𝗳𝗶𝗿𝘀𝘁 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲 𝘄𝗲 𝘁𝗵𝗶𝗻𝗸 𝗼𝗳 𝘄𝗵𝗲𝗻 𝗶𝘁 𝗰𝗼𝗺𝗲𝘀 𝘁𝗼 𝗮𝗰𝗰𝗲𝘀𝘀 𝘁𝗼 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀, 𝗯𝘂𝘁 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀’ 𝗻𝗲𝗲𝗱𝘀 𝗰𝗮𝗻 𝗴𝗼 𝗯𝗲𝘆𝗼𝗻𝗱 𝘁𝗵𝗮𝘁. Axios Global Head of Access Solutions, Omer Karfis, reminds us that patient support isn’t always about money. Some need emotional encouragement. Others need education or the chance to connect with people who truly understand their journey. Every patient’s path is different, and the right kind of support can make all the difference in helping them access and complete their treatment course.  🔗 Learn more about how Axios adapts access solutions to patient realities: https://lnkd.in/dDFTwkkk  #NeverStandStill #HealthcareAccess #AccesstoMedicine #AccesstoHealthcare

62

🎙️ Brain health and Multiple Sclerosis (MS) In the second episode of the Brain Health Mission Podcast, host Prof. Jana Midelfart-Hoff is joined by MS experts Natalia Szejko and Sanja Gluscevic to explore what brain health means for people living with MS, how to measure and improve it, and why this matters not only for individuals but for society as a whole. Listen now on Spotify, Apple Podcasts, Amazon Music, or at brainhealthmission.org #BrainHealth #BrainHealthMission #EANeurology #Neurology #MS #MultipleSclerosis #PublicHealth #Podcast

49

🩸 𝘈𝘯𝘦𝘮𝘪𝘢 𝘳𝘦𝘮𝘢𝘪𝘯𝘴 𝘰𝘯𝘦 𝘰𝘧 𝘵𝘩𝘦 𝘮𝘰𝘴𝘵 𝘴𝘦𝘳𝘪𝘰𝘶𝘴 𝘱𝘶𝘣𝘭𝘪𝘤 𝘩𝘦𝘢𝘭𝘵𝘩 𝘤𝘩𝘢𝘭𝘭𝘦𝘯𝘨𝘦𝘴 𝘨𝘭𝘰𝘣𝘢𝘭𝘭𝘺. 𝘈𝘤𝘤𝘰𝘳𝘥𝘪𝘯𝘨 𝘵𝘰 𝘵𝘩𝘦 𝘞𝘰𝘳𝘭𝘥 𝘏𝘦𝘢𝘭𝘵𝘩 𝘖𝘳𝘨𝘢𝘯𝘪𝘻𝘢𝘵𝘪𝘰𝘯 (𝘞𝘏𝘖), 40% 𝘰𝘧 𝘤𝘩𝘪𝘭𝘥𝘳𝘦𝘯 (6–59 𝘮𝘰𝘯𝘵𝘩𝘴), 37% 𝘰𝘧 𝘱𝘳𝘦𝘨𝘯𝘢𝘯𝘵 𝘸𝘰𝘮𝘦𝘯, 𝘢𝘯𝘥 30% 𝘰𝘧 𝘸𝘰𝘮𝘦𝘯 𝘢𝘨𝘦𝘥 15–49 𝘺𝘦𝘢𝘳𝘴 𝘢𝘳𝘦 𝘢𝘯𝘦𝘮𝘪𝘤. 𝘈𝘥𝘥𝘳𝘦𝘴𝘴𝘪𝘯𝘨 𝘵𝘩𝘪𝘴 𝘳𝘦𝘲𝘶𝘪𝘳𝘦𝘴 𝘯𝘰𝘵 𝘫𝘶𝘴𝘵 𝘵𝘳𝘦𝘢𝘵𝘮𝘦𝘯𝘵—𝘣𝘶𝘵 𝘦𝘢𝘳𝘭𝘺 𝘢𝘯𝘥 𝘢𝘤𝘤𝘦𝘴𝘴𝘪𝘣𝘭𝘦 𝘥𝘦𝘵𝘦𝘤𝘵𝘪𝘰𝘯.   𝘛𝘩𝘪𝘴 𝘪𝘴 𝘸𝘩𝘦𝘳𝘦 𝘈𝘐-𝘱𝘰𝘸𝘦𝘳𝘦𝘥 𝘰𝘧𝘧𝘭𝘪𝘯𝘦 𝘴𝘤𝘳𝘦𝘦𝘯𝘪𝘯𝘨 𝘥𝘦𝘷𝘪𝘤𝘦𝘴 𝘭𝘪𝘬𝘦 𝘌𝘻𝘦𝘊𝘩𝘦𝘤𝘬 𝘱𝘭𝘢𝘺 𝘢 𝘨𝘢𝘮𝘦-𝘤𝘩𝘢𝘯𝘨𝘪𝘯𝘨 𝘳𝘰𝘭𝘦. 🩸 𝐀𝐭 𝐟𝐢𝐫𝐬𝐭, 𝐥𝐞𝐭’𝐬 𝐞𝐱𝐩𝐥𝐚𝐢𝐧: 𝐖𝐡𝐚𝐭 𝐢𝐬 𝐄𝐳𝐞𝐂𝐡𝐞𝐜𝐤? #EzeCheck is a non-invasive hemoglobin screening device, already trusted globally for anemia detection. What makes it unique is that it works both online and offline—powered by advanced AI algorithms integrated within the mobile app. 🩸 𝐇𝐨𝐰 𝐄𝐳𝐞𝐂𝐡𝐞𝐜𝐤 𝐔𝐬𝐞𝐬 𝐀𝐈 𝐃𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐭𝐥𝐲 ➤  A fingertip-based biosensor collects light absorption data using absorbance spectroscopy. ➤  Instead of relying on remote servers, our AI algorithms are embedded within the mobile app itself. ➤  This means the app can interpret results instantly—even without internet connectivity. ➤  Results are stored securely on the device and synced to the cloud dashboard once online. 🩸 𝐖𝐡𝐲 𝐝𝐨𝐞𝐬 𝐭𝐡𝐢𝐬 𝐦𝐚𝐭𝐭𝐞𝐫? With AI embedded directly in the app, #EzeCheck delivers instant results without relying on central servers, eliminating delays in diagnosis. This empowers healthcare workers to conduct screenings anywhere—even in remote villages with no internet access. And once connectivity is restored, the data seamlessly syncs to the cloud, enabling smarter public health decisions through trend analysis and large-scale data insights. 🩸 𝘐𝘯 𝘤𝘰𝘯𝘤𝘭𝘶𝘴𝘪𝘰𝘯, 𝘈𝘯𝘦𝘮𝘪𝘢 𝘥𝘦𝘵𝘦𝘤𝘵𝘪𝘰𝘯 𝘯𝘰 𝘭𝘰𝘯𝘨𝘦𝘳 𝘥𝘦𝘱𝘦𝘯𝘥𝘴 𝘰𝘯 𝘤𝘰𝘯𝘯𝘦𝘤𝘵𝘪𝘷𝘪𝘵𝘺. 𝘞𝘪𝘵𝘩 𝘌𝘻𝘦𝘊𝘩𝘦𝘤𝘬, 𝘩𝘦𝘢𝘭𝘵𝘩𝘤𝘢𝘳𝘦 𝘸𝘰𝘳𝘬𝘦𝘳𝘴 𝘤𝘢𝘯 𝘴𝘤𝘳𝘦𝘦𝘯 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘰𝘧𝘧𝘭𝘪𝘯𝘦, 𝘢𝘯𝘺𝘵𝘪𝘮𝘦, 𝘢𝘯𝘺𝘸𝘩𝘦𝘳𝘦—𝘢𝘯𝘥 𝘰𝘯𝘤𝘦 𝘣𝘢𝘤𝘬 𝘰𝘯𝘭𝘪𝘯𝘦, 𝘳𝘦𝘴𝘶𝘭𝘵𝘴 𝘴𝘺𝘯𝘤 𝘴𝘦𝘢𝘮𝘭𝘦𝘴𝘴𝘭𝘺 𝘵𝘰 𝘵𝘩𝘦 𝘤𝘭𝘰𝘶𝘥 𝘧𝘰𝘳 𝘴𝘮𝘢𝘳𝘵𝘦𝘳 𝘱𝘶𝘣𝘭𝘪𝘤 𝘩𝘦𝘢𝘭𝘵𝘩 𝘪𝘯𝘴𝘪𝘨𝘩𝘵𝘴. #EzeRx #HealthcareInnovation #AnemiaAwareness #AIinHealthcare #DigitalHealth #NonInvasiveTesting #HealthcareAccessibility #PublicHealth

37

‏1‏ ‏תגובה‏

Now speaking at 🌟 Global Voices in Renal Oncology (VIRO) 2025🌟 , organized by OncoDaily: Dr. Ruzanna Papyan, Chief of the Pediatric Oncology Clinic at the Pediatric Cancer and Blood Disorders Center of Armenia, on the topic “Treating Wilms Tumor in Low-Middle-Income Countries”. 🔬 Key Takeaways from her talk: 💡 Access challenges: Pediatric surgical expertise and radiotherapy remain scarce in many LMICs, with only ~46% of African countries having radiotherapy facilities. 💡 Adapted treatment protocols: Using SIOP/COG approaches helps delay surgery and create structured treatment pathways in limited-resource settings. 💡 Collaborative progress: Initiatives like the Collaborative Wilms Tumor Africa Project, Kenya’s National Health Insurance, and global twinning programs are improving survival rates. 💡 Wilms tumor as a model: It can serve as a leading example to reach the global goal of 60% survival for childhood cancers. ✨ Dr. Papyan’s closing note: Every child with cancer, regardless of geography, deserves the chance to be cured. You can follow the full discussion here: https://lnkd.in/dC42vs5E https://lnkd.in/eX5wQnRf #RenalOncology #VIRO2025 #MedicalAdvances #WilmsTumor

28

‏1‏ ‏תגובה‏